Nucleic acid therapies offer much potential in PD, and several studies have already demonstrated that they can change the expression of essential PD proteins, including α-synuclein and its isoforms (Uehara et al., 2019; Zhao et al., 2021). This evidence concerns the gene SNCA and Parkinson disease.